The U.K. is investing £38 million in its National Biologics Manufacturing Centre, part of the country's "High Value Manufacturing Catapult" effort started several years ago to increase its presence in biologics.
The notion that a party drug could be repurposed into a "miracle" cure for severe, treatment-resistant depression is an almost irresistible story line in the popular press. And there's no reason why it can't be recycled using results from the same small, short-duration study design that long ago attracted some of the world's largest research organizations still engaged in researching new drugs in one of the most difficult fields in R&D.
With London biotech Circassia clearing about $332 million in a record-breaking U.K. IPO, a spate of other European life sciences outfits sit stage left with eyes on the public markets, stoking hopes that the stateside fervor over drug developers could cross the ocean and line their pockets.
If the U.K. adopts the two-shot model, it may use the cash it saves to vaccinate boys against HPV.
GlaxoSmithKline, which is making big investments in manufacturing in the U.K., will help its homeland try to figure out how to revive its manufacturing base.
While Finland agreed to pay out in 2011, the U.K. was still knocking back claimants in 2012. Now, though, the U.K. government is reportedly readying to pay 60 people $1.7 million each.
The United Kingdom's long history of public healthcare gives it an enviable trove of patient data. Yet this resource, which is perhaps the one true competitive edge possessed by U.K. biopharma, is at risk of being squandered as the project continues to buried by mismanagement and a blizzard of negative publicity.
Horizon Discovery Group, which makes and sells tools for genomics research and personalized medicines, has set out to raise about $41.5 million on the AIM market on the London Stock Exchange.
GlaxoSmithKline is investing £350 million in a new plant in Ulverston, U.K., that will generate 500 new jobs, increase drug capacity and potentially draw on wind power to lower its environmental impact. But what about the football fields?
Biogen Idec's hot-selling multiple sclerosis drug Tecfidera has to win reimbursement in individual European countries where governments have gotten stingy about parting with healthcare dollars. A decision Thursday by U.K. price watchdog NICE is an indication of the cost hurdles to be faced.